ClinicalTrials.gg
Not yet recruitingNCT07092267Updated Aug 14, 2025

Safety and Efficacy Evaluation of ArtiFix® Sealant Graft in Subjects Requiring Dural Repair Following Neurosurgery

An interventional study of ArtiFix® is a surgical dural sealant graft intended to close dural defects following cranial and spine surgeries. in Cerebrospinal Fluid Leak and Dural Tear, sponsored by Nurami Medical Ltd. Not yet recruiting. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Nurami Medical Ltd · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
22 Years to 65 Years
Sex
All
01

Study summary

The purpose of this clinical study is to evaluate and establish the safety and efficacy of the ArtiFix® device in subjects scheduled for cranial or spinal surgery that requires Dural repair (membrane that covers the brain and spinal cord). The investigated device will be implanted during the neurosurgical procedure and participants will be evaluated at 30, 120 and 330 days after the procedure.

02

Conditions studied

  • Cerebrospinal Fluid Leak
  • Dural Tear
03

In context

Cerebrospinal Fluid Leak

41 studies on the registry are indexed under Cerebrospinal Fluid Leak; 9 are open to participants now.

This study's planned enrollment of 20 is below the median of 74 across 24 interventional studies indexed under Cerebrospinal Fluid Leak.

Browse Cerebrospinal Fluid Leak studies →

Lead sponsor

Nurami Medical Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject between the ages of 22-65 (inclusive)
  2. Subject is scheduled for an elective cranial or spinal surgery with a single dural defect that could not be completely repaired by primary suture. The dural defect must not exceed 6cm2 (e.g. defects of sizes 2cm X 3cm, 1cm X 5cm, can be included). The defect can be completely repaired/closed by a dural sealant graft with an overlap of 6 mm with the surrounding intact dura (only 1 graft can be implanted in each subject in a single location).
  3. Subject has undergone imaging (such as, CT or MRI) in the past 6 months before enrolment.
  4. Surgical wound is expected to be Class I/clean.
  5. Subject understands the study requirements and procedures, can provide written and is able and willing to adhere to the required follow-up visits and testing.

Exclusion criteria

Exclusion Criteria:

  1. Subject has known hydrocephalus.
  2. Subject is unable to undergo MRI after the surgery.
  3. Subject's is less than 12 months.
  4. Significant intraoperative hemorrhage that mandates blood transfusion.
  5. Subject has a local or systemic infection (e.g. urinary tract infection (UTI), active pneumonia etc.) or evidence of any surgical site infection, fever > 38.3°C, positive blood culture and/or a positive chest x-ray for acute inflammatory process.
  6. Subject has acquired or congenital compromised immune system and/or disease, and/or is taking chronic agents at baseline.
  7. Subject will require use of other forms of dural repair (i.e. dural graft or sealant).
  8. Subject is intended to undergo craniectomy wherein bone flap will not be returned.
  9. Subject with a compromised wound healing process due to past treatments (e.g. chemotherapy, radiation therapy, severe diabetes etc.) or other concurrent conditions (e.g. long-standing treatment).
  10. Subject has been clinically diagnosed with (other than basal cell carcinoma or low-grade glioma), uncontrolled diabetes (>6.5%), sepsis, and systemic collagen disease.
  11. Subject had chemotherapy and/or radiotherapy in the past 12 weeks before surgery or is planned to have chemotherapy or radiotherapy less than 12 weeks after surgery.
  12. Subject is an acute cranial trauma surgical case or had intracranial hemorrhage from any cause (hemorrhagic stroke, ruptured aneurysm etc.).
  13. Subject that has a concurrent disease or symptoms or conditions that would place the patient in excessive risk to the planned surgery - defined by PI.
  14. Subject had a previous neurosurgery in the same anatomical site.
  15. Subject was diagnosed with coagulopathy as determined by the surgeon.
  16. Subject is participating in another clinical trial using devices/drugs
  17. Subjects who previously participated in any investigational drug or device study within 30 days of screening
  18. Subject has known history of sensitivity or allergy to any component of the ArtiFix®.
  19. Female subjects who are breastfeeding, pregnant or interested in becoming pregnant during the duration of the study.
  20. Any condition or abnormality which in the opinion of the investigator may jeopardize the subject's safe participation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Subjects requiring Dural repair during elective neurosurgery procedures.

    Men and women scheduled for an elective cranial or spinal surgery that requires Dural repair during elective neurosurgery procedure. The investigated device is a surgical Dural sealant graft intended to close Dural defects.

    Device: ArtiFix® is a surgical dural sealant graft intended to close dural defects following cranial and spine surgeries.

Interventions

  • DeviceArtiFix® is a surgical dural sealant graft intended to close dural defects following cranial and spine surgeries.

    ArtiFix® is a synthetic surgical dural sealant graft intended to close dural defects following cranial and spine surgeries. ArtiFix® adheres to the dura, so that sutures are not required to prevent cerebrospinal fluid (CSF) leakage.

06

What researchers measure

Primary outcomes

  1. Evaluation of CSF leakage rate up to 120 days after ArtiFix® implantation.

    Time frame: up to 120 days after ArtiFix® implantation

Secondary outcomes

  1. Evaluation of CSF leakage rate via MRI at 120 days after ArtiFix® implantation Evaluation of CSF leakage rate via MRI at 330 days after ArtiFix® implantation

    Time frame: at 120 and 330 days after ArtiFix® implantation.

  2. To evaluate the frequency and severity of device-related adverse events, up to 330 days post ArtiFix® implantation.

    Time frame: up to 330 days post ArtiFix® implantation.

  3. Wound healing at implant site up to 30 days after implantation.

    Time frame: Up to 30 days after implantation.

  4. Device Handling Characteristics, as reported by the surgeon [e.g. Ease of Use, Strength, Seal Quality, Reapplication (if occurred), adhesion to surgical tools]. Device Handling Characteristics reported by user experience questionnaire.

    Time frame: Following investigational device implantation on the day of the surgical procedure.

  5. Magnetic Resonance Imaging at the 120 and 330 days follow-up, to determine the presence or absence of the following conditions: • Adhesion formation • Scarring • Brain edema adjacent to device implant site

    Time frame: At the 120 and 330 days follow-up visits

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2025; primary completion for Nov 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Jul 29, 2025
StartEst.
Nov 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07092267
Lead sponsor
Nurami Medical Ltd
Collaborators
KCRI
Responsible party
Sponsor
First posted
Jul 29, 2025
Start date
Nov 2025 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Aug 14, 2025

Study contacts

Amir Bahar
Contact
amir@nurami-medical.com
+972-54-4487673
Jenny Krupko
Contact
jenny@nurami-medical.com
+972-50-5968319
Joseph Milbaum
study director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion